- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
IVI Launches 2-Year Health Equity Initiative
The Innovation and Value Initiative (IVI) announced the launch of its Health Equity Initiative, a 2-year initiative that aims to define gaps in value assessment methodology and develop best practices that support health equity.
Alexandria, Virginia — The Innovation and Value Initiative (IVI) announced the launch of its Health Equity Initiative, a 2-year initiative that aims to define gaps in value assessment methodology and develop best practices that support health equity.
The IVI Health Equity Initiative’s goals include:
- Advancing our understanding of why health equity considerations in value assessment are important
- Identifying gaps in data collection and methods practices and implications related to health equity
- Developing “best practice” protocols that inform the practice of value assessment and health technology assessment (HTA) to mitigate these gaps
- Achieving multi-stakeholder consensus about areas for further research, scientific practice change, and policy development
“Through this work, IVI has found that without a consistent and intentional focus on equity, we are blind to key differences among patients. Also, current assessments run the risk of reinforcing or even exacerbating inequities that already exist in the US health care system,” noted Rick Chapman, PhD, chief science officer, IVI.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More
